表1_我们开发的同源重组缺陷特征在胃癌预后和药物敏感性中的潜在价值.DOCX

数据集获取（Figshare）

• 源站标题：Table1_Potential value of the homologous recombination deficiency signature we developed in the prognosis and drug sensitivity of gastric cancer.DOCX
• DOI：10.3389/fgene.2022.1026871.s008
• 发布日期：2022-11-16
• 文件数：1 个
• 文件总体积：13.15 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Table1_Potential_value_of_the_homologous_recombination_deficiency_signature_we_developed_in_the_prognosis_and_drug_sensitivity_of_gastric_cancer_DOCX/21563037

命令行下载

curl -L -o "Table1_Potential value of the homologous recombination deficiency signature we developed in the prognosis and drug sensitivity of gastric cancer.DOCX" "https://ndownloader.figshare.com/files/38224044"

文件清单

• Table1_Potential value of the homologous recombination deficiency signature we developed in the prognosis and drug sensitivity of gastric cancer.DOCX（13.15 KB）

文件总体积 13.15 KB（源站 API 实测）。

数据说明

Background: Homologous recombination is an important DNA repair mechanism, which deficiency is a common feature of many cancers. Defining homologous recombination deficiency (HRD) status can provide information for treatment decisions of cancer patients. HRD score is a widely accepted method to evaluate HRD status. This study aimed to explored HRD in gastric cancer (GC) patients’ clinical outcomes with genes related to HRD score and HRD components score [HRD-loss of heterozygosity (LOH), large-scale state transitions (LST), and telomeric allelic imbalance (NtAI)].
Methods: Based on LOH, NtAI scores, LST, and integrated HRD scores-related genes, a risk model for stratifying 346 TCGA GC cases were developed by Cox regression analysis and LASSO Cox regression. The risk scores of 33 cancers in TCGA were calculated to analyze the relationship between risk scores of each cancer and HRD scores and 3 HRD component scores. Relationship between the risk model and patient survival, BRCA1, BRCA2 mutation, response to Cisplatin and Talazoparib treatment was analyzed by generating Kaplan-Meier curve, mutations waterfall map and conducting Pearson correlation analysis.
Results: An gene signature was constructed based on 11 HRD scores-related gene (BEX2, C1QL2, DKK1, DRC1, GLUD2, HCAR1, IGFBP1, NXPH1, PROC, SERPINA5, and SLCA1A2). Risk groups were stratified by risk score. Prognosis of the high-risk score group was worse than the low-risk ones. Risk score was associated with BRCA2 mutation, and patients grouped according to BRCA2 mutation status had distinguishable risk score, NtAI score, HRD-LOH, LST, and HRD scores. The low-score group showed higher sensitivity to Cisplatin and Talazoparib. The risk score of adrenocortical carcinoma (ACC), stomach adenocarcinoma (STAD), uterine corpus endometrial carcinoma (UCEC), kidney renal clear cell carcinoma (KIRC), sarcoma (SARC), prostate adenocarcinoma (PRAD), breast invasive carcinoma (BRCA) was significantly positively correlated with HRD score.
Conclusion: We developed an 11 HRD scores-related genes risk model and revealed the potential association between HRD status and GC prognosis, gene mutations, patients’ sensitivity to thera

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fgene.2022.1026871.s008（source: https://frontiersin.figshare.com/articles/dataset/Table1_Potential_value_of_the_homologous_recombination_deficiency_signature_we_developed_in_the_prognosis_and_drug_sensitivity_of_gastric_cancer_DOCX/21563037）。